Osimertinib Mesylate Cas:1421373-66-1
AZD9291(mesylate), osimertinib mesylate, is indicated for disease progression during or after previous treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). And to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been tested positive for the EGFRT790M mutation. AZD9291(Chemicalbook salt mesylate) was highly selective, with IC50 of 11.4nM and 12.9nM for T790M/L858R mutation and exon 19 deletion EGFR, respectively, while its inhibitor activity against wild-type EGFR (IC50) was 494nM. Osimertinib is an irreversible inhibitor of EGFR and can form covalent bonds with molecular targets, so the theoretical response lasts longer and the chance of resistance is correspondingly reduced.
Product Introduction：
Osimertinib Mesylate Cas:1421373-66-1 belongs to a class of drugs called kinase inhibitors, which work by blocking the action of an abnormal protein that signals cancer cells to multiply, so this helps stop or slow the spread of cancer cells and may help shrink tumours. Our product reduces the risk of disease recurrence or death by 79% and is generally used to treat metastatic non-small cell lung cancer in patients with an abnormal epidermal growth factor gene.
Features:
1. The use of our Osimertinib Mesylate Cas:1421373-66-1 does not fall under the category of chemotherapy, but rather targeted therapy. It does not kill rapidly dividing cells or affect healthy cells in the body.
2. Drinking alcohol (in small amounts) does not appear to affect the safety or effectiveness of Ocitinib, but may cause male infertility.
3. Although patients usually respond well to it, most will develop resistance after one year of treatment, at which point the drug must be stopped. Resistance occurs because of mutations in the EGFR protein, which cause the drug to bind less tightly.
Specification：
Name: Osimertinib mesylate
Molecular Formula: C28H33N7O2.CH4O3S
EINECS:200-064-1
